Article Information
PubMed
Published By
Print ISSN
Online ISSN
History
- Received September 4, 2020
- Accepted December 21, 2020
- Published online February 4, 2021.
Article Versions
- You are currently viewing a previous version of this article (February 4, 2021 - 07:28).
- View the most recent version of this article
Copyright & Usage
©The authors 2021. For reproduction rights and permissions contact permissions@ersnet.org
Author Information
- William W. Busse1,
- Monica Kraft2,
- Klaus F. Rabe3,4,
- Yamo Deniz5,
- Paul Rowe6,
- Marcella Ruddy5 and
- Mario Castro7
- 1UW Allergy, Pulmonary and Critical Care Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA
- 2University of Arizona Health Sciences Center, Tucson, AZ, USA
- 3LungenClinic Grosshansdorf (member of the German Center for Lung Research [DZL]), Airway Research Center North (ARCN), Grosshansdorf, Germany
- 4Christian-Albrechts University (member of the German Center for Lung Research [DZL]), Airway Research Center North (ARCN), Kiel, Germany
- 5Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA
- 6Sanofi, Bridgewater, NJ, USA
- 7University of Kansas School of Medicine, Kansas City, KS, USA
- William W. Busse, Clinical Science Center, 600 Highland Ave, Madison, WI 53792-0001, USA. E-mail: wwb{at}medicine.wisc.edu
Funding
Sanofi
Regeneron Pharmaceuticals
Article usage
Altmetrics
Vol 61 Issue 3
Table of Contents
Understanding the key issues in the treatment of uncontrolled persistent asthma with type 2 inflammation
